UTI & STI Molecular Diagnostics

Faster UTI & STI Diagnosis with Rapid PCR Testing and PharmD Treatment Guidance

Urinary tract infections (UTIs) and sexually transmitted infections (STIs) are among the most common—and often misdiagnosed—infections in clinical practice. Delayed or inaccurate diagnosis can lead to complications, unnecessary antibiotic use, and increased risk of antimicrobial resistance.

At CuraPath Dx, we provide a modern, evidence-based approach: PCR-based molecular testing for UTIs and STIs, combined with PharmD-reviewed treatment guidance—delivering accurate, actionable results within 24 hours.

The Limitations of Conventional Testing

Traditional urine cultures and standard STI assays have significant drawbacks:

  • Slow Turnaround: Urine culture results typically take 48–72 hours, delaying targeted treatment.
  • Incomplete Detection: Some fastidious bacteria and mixed infections may go undetected by culture methods.
  • False Negatives: Prior antibiotic exposure can suppress culture growth, masking the true infection.
  • Limited Resistance Insights: Sensitivity testing may not reveal genetic resistance mechanisms, particularly for certain STIs.

For sexually transmitted infections, conventional NAAT panels may only target a limited set of pathogens—missing co-infections that influence treatment decisions.

Our Solution: Rapid Multiplex PCR for UTI & STI Pathogens

Our diagnostic platform uses real-time PCR to detect and differentiate key bacterial, fungal, and protozoal pathogens, along with relevant resistance markers, from a single urine or swab specimen.

Key Features:

  • Comprehensive Pathogen Coverage:
    • UTI panel detects common uropathogens (E. coli, Klebsiella pneumoniae, Proteus mirabilis, and more) and select fungi.
    • STI panel includes Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Mycoplasma genitalium, Ureaplasma urealyticum, and select herpesvirus targets.
  • Resistance Marker Detection: Identifies genes associated with resistance to beta-lactams, fluoroquinolones, macrolides, and other classes.
  • Rapid Turnaround: Electronic results within 24 hours of specimen receipt.
  • Semi-Quantitative Reporting: Pathogen load categorized as High, Moderate, or Low for clinical context.

PharmD-Led Treatment Guidance

Each positive result is reviewed by a Doctor of Pharmacy (PharmD) specializing in infectious disease and antimicrobial stewardship. This value-added service includes:

  • Pathogen-Specific Recommendations: Tailored antibiotic or antiviral guidance based on detected organisms and resistance markers.
  • Drug Safety & Interaction Review: Identifies potential interactions, allergy concerns, and contraindications.
  • Chart-Ready Stewardship Notes: Concise documentation to support clinical decision-making, compliance, and audits.

This ensures providers receive both the diagnostic data and the clinical interpretation necessary to initiate appropriate therapy without delay.

Benefits for Providers and Patients

Clinical Advantages:

  • Faster Targeted Therapy: Enables same-day treatment adjustments, improving outcomes and reducing complications.
  • Enhanced Detection: Identifies co-infections and resistant organisms that may be missed by traditional methods.
  • Supports Antimicrobial Stewardship: Reduces unnecessary or ineffective antibiotic use.

Who We Serve

This testing service is designed for:

  • Primary Care & Urgent Care Clinics treating acute UTI or STI presentations
  • Urology & Gynecology Practices managing recurrent or complicated infections
  • Public Health & Sexual Health Clinics aiming to improve testing efficiency and reduce transmission
  • Long-Term Care Facilities where UTIs are a major cause of hospitalization

Partner with Us

Our integrated UTI/STI molecular testing and PharmD-guided reporting service empowers clinicians to deliver faster, more precise, and safer patient care.

Scroll to Top